Eating disorders can result in a spectrum of morbidity, or even death, and imaging can play a role in diagnosing these potentially treatable illnesses, according to an article published in the April issue of the American Journal of Roentgenology.

The Centers for Medicare & Medicaid Services (CMS) released a proposed decision memo that outlined its suggestion to cover PET imaging for most solid tumors. CMS noted that PET monitoring of Medicare beneficiaries with prostate cancer is not reasonable and necessary.

A number of research breakthroughs in molecular imaging and molecular-targeted treatments of thyroid cancer are showing signs of expansion into the clinic, according to a review in the March issue of The Lancet.

The amyloid imaging agent F-18 florbetaben has been moving forward in clinical trials for the diagnosis of Alzheimer’s disease. The up and coming F-18 florbetaben is showing signs of similar effectiveness, according to research published in the May issue of The Journal of Nuclear Medicine that presented a dynamic model of amyloid imaging using the tracer.

Brain activity analyzed with functional MRI (fMRI) has shown convicted criminals with relatively low anterior cingulate activity were twice as likely to be rearrested as offenders with high activity in this region, according to research published online March 27 in Proceedings of the National Academy of Sciences.

TUSTIN, Calif., April 1, 2013 – Toshiba America Medical Systems, Inc. announced today that Nancy Gillen has been named vice president, Marketing. Gillen will manage all marketing activities, including business units, corporate communications and research with the goal to build on Toshiba’s record in customer satisfaction.

Clinical and commercial leaders from GE Healthcare and Dorcy Cancer Center at St. Mary-Corwin Medical Center in Pueblo, Colorado, joined together today for a special tour to honor the Center’s continuing innovation in cancer care.

SHINE Medical Technologies, Inc. (SHINE), a Wisconsin-based company dedicated to being the world leader in safe, clean, and affordable production of medical isotopes and cancer treatment elements, has submitted its Construction Permit application to the Nuclear Regulatory Commission (NRC). This submittal is the first formal step by SHINE in seeking an NRC permit to begin construction of its medical isotope facility in Janesville, Wisconsin.